These are the stocks posting the largest moves before the bell Monday.Market Insiderread more
Trump says he would impose additional sanctions against Iran in a bid to prevent the country obtaining nuclear weapons.World Politicsread more
The major indexes have stretched to all-time highs and are riding one of their best first halves in decades.Trading Nationread more
Tensions between the U.S. and Iran will likely escalate in the near future, a former adviser to the Iranian government said on Monday.Energyread more
Millennial stocks are looking fly this month, and one name could be on the verge of exploding in the next year.Trading Nationread more
Chinese vice commerce minister said Monday that Beijing would like the U.S. to cancel "inappropriate" actions against Chinese companies.China Economyread more
Eldorado Resorts has agreed to merge with Caesars Entertainment in a cash and stock deal that values its peer at about $17.3 billion including debt.Casinos and Gamingread more
A decisive win for Turkey's main opposition party in a re-run of a mayoral election in Istanbul has prompted hopes for reforms.Europe Politicsread more
Sixteen Asia Pacific countries have been negotiating the Regional Comprehensive Economic Partnership since 2013, with India's reluctance to open up its markets a major...Asia Economyread more
Internships for professionals who've taken a break from the labor force are becoming more popular at financial advisory firms. Returnships provide a particularly good way to...FA Playbookread more
The secretary of State said he was traveling to Saudi Arabia and the United Arab Emirates to make sure that the U.S. is "strategically aligned" with its allies.Politicsread more
UBS slashed Pfizer's rating to neutral from buy on Wednesday, citing the so-called "patent cliff" in the coming years on key products that would greatly offset revenue growth. The bank also cut its 12-month price target for Pfizer to $46 from $48.5.
"Xeljanz, Ibrance, Xtandi, Eliquis and Tafamidis totalling $20 billion of sales (about 30 percent of total revenue in 2015) all lose patent protection from 2025 to 2029 and our valuation blend of discounted cash flow and price per earnings does not ignore this dynamic," UBS' pharmaceuticals analyst Navin Jacob said in a note.
BMO downgraded Merck to market perform from outperform, saying Wall Street's expectations for the drugmaker are too high given its over-dependence on the drug Keytruda. The bank kept its price target for Merck unchanged at $80.
"We've been Merck bulls because of Keytruda; however, the Street's Keytruda expectations are now meaningfully above ours, and seem to overlook competitive risks. We expect four to five competitor IO trial readouts in 2019 that have the potential to produce competitive results, and increase uncertainty," BMO's pharmaceuticals analyst Alex Arfaei said in a note.
Shares of Pfizer fell 1 percent to $41.95 in per-market trading on Wednesday, while Merck stock is down 1 percent to $75.15. Both companies outperformed the market last year as Pfizer returned more than 20 percent and Merck gained 35 percent.